The New England journal of medicine, 2023-01, Vol.388 (1), p.9-21
2023
Details
- Autor(en) / Beteiligte
- Titel
- Lecanemab in Early Alzheimer’s Disease
- Ist Teil von
- The New England journal of medicine, 2023-01, Vol.388 (1), p.9-21
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- In a phase 3 trial, participants with early Alzheimer’s disease who received the monoclonal antibody lecanemab had less decline on measures of cognition and function at 18 months than those who received placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2212948Titel-ID: cdi_hal_primary_oai_HAL_hal_04480205v1
- Format
- –
- Schlagworte
- Activities of Daily Living, Aging, Alzheimer Disease, Alzheimer Disease - diagnostic imaging, Alzheimer Disease - drug therapy, Alzheimer's disease, Amyloid beta-Peptides - cerebrospinal fluid, Amyloid beta-protein, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - pharmacology, Antibodies, Monoclonal, Humanized - therapeutic use, Biomarkers, Body weight, Care and treatment, Cerebrospinal fluid, Clinical trials, Cognition - drug effects, Cognitive ability, Coronaviruses, COVID-19, Dementia, Dementia disorders, Development and progression, Diagnosis, Double-Blind Method, Drug dosages, Edema, FDA approval, Geriatrics, Health aspects, Humans, Immunoglobulin G, Intravenous administration, Life Sciences, Magnetic resonance imaging, Measurement, Memory, Monoclonal antibodies, Neurodegenerative diseases, Neuroimaging, Neurology, Neurosurgery, Nootropic Agents - adverse effects, Nootropic Agents - pharmacology, Nootropic Agents - therapeutic use, Placebos, Positron emission tomography, Psychiatry, Psychiatry General, Technical communication